Search PubMed⌕ Search

Biomedical subjects

K Furihata

Publications and source records attributed to K Furihata.

At least 163 records · Page 9Linked to original sources
PubMed1988

Identification of Bakb, a new platelet-specific antigen associated with posttransfusion purpura.

Baka is a platelet alloantigen whose putative allele, Bakb, has not been identified previously. By using a serum, "Har," obtained from a patient with posttransfusion purpura, we describe the platelet alloantigen Bakb. The Har serum reacted with an NP-40-extractable platelet membrane protein of 142 kd with mobility similar to platelet glycoprotein IIb alpha. We found that the antigen recognized by the Har serum is inherited in an autosomal dominant mode with an apparent gene frequency of .39. Chi-square analysis of observed and expected phenotype frequencies indicated that serum Har recognizes Bakb, the anticipated allele of Baka. Our findings provide new evidence for polymorphism of glycoprotein IIb and for the association of posttransfusion purpura with alloimmunization to determinants on this glycoprotein.

Antigens, Human Platelet↗
PubMed1987

On the association of the platelet-specific alloantigen, Pena, with glycoprotein IIIa. Evidence for heterogeneity of glycoprotein IIIa.

Neonatal alloimmune thrombocytopenic purpura associated with a new platelet-specific alloantigen Pena has been reported. We now provide direct evidence that the Pena determinant is associated with glycoprotein (GP) IIIa, but that it is distinct from epitopes that define the PlA system. By ELISA wherein monoclonal antibodies specific for GPIIb (Tab) and specific for GPIIIa (AP3) were used to capture and hold antigens from a platelet lysate prepared under conditions that generate free GPIIb and GPIIIa, anti-Pena reacted with GPIIIa held by AP3 but not with GPIIb held by Tab. In an alternative ELISA where purified GPIIIa from both PlA1-positive and PlA1-negative platelets were used individually as antigen, anti-Pena reacted with both allelic forms of GPIIIa. By radioimmuno-precipitation, anti-Pena precipitated a single surface-labeled membrane protein with electrophoretic characteristics in sodium dodecyl sulfate-polyacrylamide gels, under nonreduced or reduced conditions, identical to those of GPIIIa. By fluorocytometry, platelets from several donors, regardless of PlA phenotype, bound an amount of anti-Pena roughly equivalent to one-half that amount of anti-PlA1 bound by PlA1 homozygous (A1/A1) platelets and roughly equal to that amount of anti-PlA1 bound by PlA1 heterozygous (A1/A2) platelets. Using platelets from donors typed homozygous for PlA1 and Pena in a quantitative indirect binding assay, 14-24,000 molecules of anti-Pena and 41-51,000 molecules of anti-PlA1 were bound per platelet at saturation. Anti-Pena completely inhibited ADP-induced aggregation of Pena-positive platelets, regardless of PlA phenotype. These results indicate that the Pena determinant is associated with GPIIIa but distinct from PlA.

Antigens, Human Platelet↗
PubMed1987

Arugomycin, a new anthracycline antibiotic. I. Taxonomy, fermentation, isolation and physico-chemical properties.

Arugomycin (AGM) is a new anthracycline antibiotic produced by strain No. 1098-AV2 which was identified as Streptomyces violaceochromogenes. AGM was isolated by solvent extraction, silicic acid chromatography and Sephadex LH-20 column chromatography. Acid treatment of AGM gave the chromophore, named arugorol, which was identified as 4'-epi-nogalarol, and sugar moieties. AGM inhibited the growth of Gram-positive bacteria and showed antitumor activity against sarcoma S-180 and Ehrlich ascites tumors.

Animals↗
PubMed1987

Arugomycin, a new anthracycline antibiotic. II. Structural elucidation.

The structure of arugomycin was determined by chemical degradation, and NMR and mass spectral analyses to be a new anthracycline antibiotic with arugorol (4'-epi-nogalarol) as the chromophore and two sugar chains comprising diginosyl-decilonitrosyl-2-deoxyfucose, and (4-O-fumaryl-diginosyl)-diginosyl-2-deoxyfucosyl -diginose.

Anthracyclines↗
PubMed1986

Induction of antibiotic production with ethidium bromide in Streptomyces hygroscopicus.

Protoplast regeneration carried out in a carriomycin producing organism, Streptomyces hygroscopicus 358 AV2, lose carriomycin productivity without loss of carriomycin-resistance and the ability of formation of aerial mycelium. Ethidium bromide treatment on the 358 AV2 strain generated a bald mutant that produced carriomycin and a new antibiotic curromycin. In some other media, however, the parent strain produced curromycin, indicating that the ethidium bromide treatment altered the regulation of antibiotic production. Ethidium bromide treatment on a protoplast-regenerated strain derived from the parent strain resulted in derivatives capable of producing carriomycin and curromycin. These strains were unstable and tended to lose the recovered antibiotic productivity easily.

Acridine Orange↗
PubMed1986

A novel macrolide antibiotic, notonesomycin A.

Fermentation of Streptomyces aminophilus subsp. notonesogenes 647-AV1 produced a mixture of antifungal antibiotics. Notonesomycin A, the main component has been characterized as a new macrolide antibiotic containing a sulfate group, a malonate moiety, two deoxysugars and a 1,3,4-trisubstituted benzene system in the molecule. It was active against some fungi and Gram-positive bacteria in vitro and effective against the sheath blight disease of rice plant in a green house test.

Animals↗